Citius Pharmaceuticals, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended September 30, 2022. This is an annual report, not a quarterly filing. The company is a development-stage biopharmaceutical business with no product revenue to date.
Financial performance and position
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $17.7 million | $12.2 million |
| General and administrative expense | $11.8 million | $9.8 million |
| Stock-based compensation expense | $3.9 million | $1.5 million |
| Total operating expenses / operating loss | $33.3 million | $23.5 million |
| Net loss | $33.6 million | $23.1 million |
| Net cash used in operating activities | $28.4 million | $24.3 million |
| Cash and cash equivalents at year-end | $41.7 million | $70.1 million |
Loss per share was $0.23 in both years; weighted-average shares rose to 146.1 million from 108.6 million. Gross margin is not meaningful because the company reported no revenue. Operating costs increased, principally from I/ONTAK development and BLA preparation, expanded Mino-Lok trial activity, Halo-Lido’s Phase 2b study, and higher compensation and stock-based compensation.
Total assets were $114.0 million, total liabilities $10.6 million, and stockholders’ equity $103.4 million at September 30, 2022. The balance sheet shows no conventional debt outstanding; liabilities mainly included accounts payable, accruals, lease obligations, and a deferred tax liability. Working capital was approximately $40 million. The company reported no off-balance-sheet arrangements.
Business and material developments
- I/ONTAK (E7777): The company filed a biologics license application for cutaneous T-cell lymphoma in September 2022; the FDA accepted it in December 2022, after the fiscal year-end. The pivotal trial reported an independent-review objective response rate of 36.2% (95% CI 25.0%–48.7%); the FDA indicated its efficacy assessment would consider response magnitude, duration, and risk-benefit.
- Mino-Lok: Phase 3 enrollment and event collection were ongoing. The filing reports 169 enrolled versus a planned 144, 72 catheter-failure events versus 92 required, and 17 patients still in treatment or pending completion data, with enrollment completion expected in 2023. The trial had been delayed, including by COVID-19-related site impacts.
- Halo-Lido: A Phase 2b dose-ranging trial began in April 2022, with approximately 300 patients planned and a readout expected in the second half of 2023.
- Mino-Wrap: The company was pursuing preclinical work following FDA feedback and anticipated filing an IND in 2023.
- NoveCite: Its iPSC-derived mesenchymal stem-cell program for ARDS remained preclinical. Citius owned 75% of NoveCite; the license includes potential milestone payments of up to $51 million and royalties.
- Proposed I/ONTAK spinoff: Announced in May 2022, the planned transaction was targeted for calendar 2023, subject to board approval, market conditions, regulatory approvals, and SEC filings; completion was not assured.
Outlook, risks, and unusual items
Management estimated that cash on hand would fund operations through December 2023 and said it did not anticipate seeking additional capital until sometime in 2023. In November 2022, the company was selected for a New Jersey tax certificate transfer program expected to provide $3.6 million of non-dilutive capital by late 2022 or early 2023. The company expects R&D spending to increase in fiscal 2023 across I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and NoveCite.
Key risks include ongoing losses and no operating revenue; the need for additional financing beyond the stated runway; uncertainty of clinical outcomes, FDA decisions, and commercial acceptance; reliance on third-party research organizations and manufacturers; reimbursement, pricing, and commercialization challenges; COVID-19-related trial disruption; potential dilution; and Nasdaq listing compliance. The company reported 38.3 million shares underlying warrants and 9.4 million underlying options at year-end. Mino-Lok and Halo-Lido’s planned 505(b)(2) pathways may require additional data or face other regulatory or patent delays. No material litigation was reported.
FY2022 included $576,000 of deferred income tax expense related to tax amortization of in-process research and development. The FY2021 comparison included a $166,557 gain from forgiveness of the PPP loan and a $1.45 million deemed dividend related to warrant extensions. The independent auditor issued an unqualified opinion and reported no critical audit matters; management concluded disclosure controls and internal control over financial reporting were effective.
Important facts for investors to verify
- Current cash, burn rate, financing plans, and whether the expected December 2023 runway and $3.6 million state-program proceeds were realized.
- FDA review milestones, information requests, and ultimate decision for the I/ONTAK BLA; the filing’s acceptance announcement occurred after fiscal year-end.
- Mino-Lok’s updated enrollment, required failure events, trial timing, and any FDA-agreed endpoint or analysis changes.
- Halo-Lido Phase 2b progress and readout timing, and Mino-Wrap’s progress toward IND submission.
- Whether the proposed I/ONTAK spinoff was approved and completed, and its impact on Citius’s remaining assets and financing needs.
- Potential dilution from outstanding warrants and options, as well as milestone, royalty, and sublicense obligations under product licenses.